James MD - Oncimmune Holdings Chief US
| ONC Stock | 1.75 0.74 29.72% |
Executive
James MD is Chief US of Oncimmune Holdings plc
| Address | 1 Park Row, Leeds, United Kingdom, LS1 5AB |
| Phone | 44 1157 840 500 |
| Web | https://www.oncimmune.com |
Oncimmune Holdings Management Efficiency
The company has return on total asset (ROA) of (0.3023) % which means that it has lost $0.3023 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.6096) %, meaning that it generated substantial loss on money invested by shareholders. Oncimmune Holdings' management efficiency ratios could be used to measure how well Oncimmune Holdings manages its routine affairs as well as how well it operates its assets and liabilities. At present, Oncimmune Holdings' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 664.3 K, whereas Total Current Assets are forecasted to decline to about 2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marika Clemow | Auction Technology Group | 40 | |
| Jayne Meacham | Auction Technology Group | N/A | |
| Xuesong CFA | Polar Capital Technology | N/A | |
| Vicky Edwards | Alfa Financial Software | N/A | |
| Benjamin Rogoff | Polar Capital Technology | N/A | |
| Sebastien Gerland | Pfeiffer Vacuum Technology | N/A | |
| Yunfeng Song | Sunny Optical Technology | 59 | |
| Philipp Brandenstein | Rheinmetall AG | N/A | |
| Turner Parlin | Alfa Financial Software | N/A | |
| Wyatt Barrett | Auction Technology Group | N/A | |
| Michael Salzmann | Rheinmetall AG | N/A | |
| Peter Rcker | Rheinmetall AG | N/A | |
| Lesa Musatto | Auction Technology Group | 57 | |
| Luke Rogers | Eastinco Mining Exploration | N/A | |
| Suzie Ryu | Auction Technology Group | N/A | |
| Pratyush Rai | Auction Technology Group | N/A | |
| Richard Dewire | Alfa Financial Software | N/A | |
| Nicholas Evans | Polar Capital Technology | N/A | |
| James Paul | Alfa Financial Software | N/A | |
| Paul CFA | Polar Capital Technology | N/A | |
| Dan Pennington | Auction Technology Group | 39 | |
Management Performance
| Return On Equity | -7.61 | ||||
| Return On Asset | -0.3 |
Oncimmune Holdings plc Leadership Team
Elected by the shareholders, the Oncimmune Holdings' board of directors comprises two types of representatives: Oncimmune Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncimmune. The board's role is to monitor Oncimmune Holdings' management team and ensure that shareholders' interests are well served. Oncimmune Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncimmune Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA FCA, Exec | ||
| BSc FRCP, Chief Officer | ||
| James MD, Chief US | ||
| Adam Hill, CEO Director | ||
| Shane Smith, VP Oncimmune | ||
| Maarten Brusse, Chief Asia | ||
| Ron Kirschner, General COO | ||
| Cla Rosenfeld, Head Relations | ||
| Petra Budde, Chief Officer | ||
| Martin Hudson, Finance Director | ||
| Matthew Hall, Chief Officer | ||
| Martin Gouldstone, CEO Director | ||
| MD BSc, Chief Officer | ||
| Cameron Barnard, Chief Officer |
Oncimmune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncimmune Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.61 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (1.32) % | ||||
| Operating Margin | (1.18) % | ||||
| Current Valuation | 7.06 M | ||||
| Shares Outstanding | 111.77 M | ||||
| Shares Owned By Insiders | 31.59 % | ||||
| Shares Owned By Institutions | 39.27 % | ||||
| Price To Book | 49.27 X | ||||
| Price To Sales | 0.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Oncimmune Stock
Oncimmune Holdings financial ratios help investors to determine whether Oncimmune Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncimmune with respect to the benefits of owning Oncimmune Holdings security.